Sunday, November 1, 2015

Olapalib in metastatic PCa




Pca is a heterogeneous diesease and hence would probably respond well with polymerase inhibition. The New England Journal of Medicine posted a report on 29 October 2015 on the successful trials of Olapalip. PCa patients who had not responded to standard treatments and who had defects in their DNA repair genes achieved a high degree of success.

Olaparib is produced by AstraZeneca and recently approved by the FDA.

Visit site below for full report:



Good things are a-coming.
Take care


Allen Lai


3 comments: